2. Protein Tyrosine Kinase/RTK
  3. FGFR
  4. Bemarituzumab

Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer.

For research use only. We do not sell to patients.

CAS No. : 1952272-74-0

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Bemarituzumab Featured Recommendations:

Bemarituzumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Humanized
In Vitro

Bemarituzumab (0.001-100 μg/mL, 30 min) inhibits FGF7-induced FGFR2 phosphorylation and cell proliferation in a concentration-dependent manner in the SNU-16 human gastric cancer cells, reaching a maximal value at ≥6.25 μg/mL[2].
Bemarituzumab exhibits immune cell-mediated killing of tumor cells overexpressing FGFR2b[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bemarituzumab Related Antibodies
In Vivo

Bemarituzumab (1-5 mg/kg; i.v.; twice a week) inhibits tumor growth in a dose-dependent manner and causes tumor regression in some mice in the xenograft mouse model of OCUM-2M human gastric cancer cells[2].
Bemarituzumab (5 mg/kg; i.p.; twice a week) combined with 5-fluorouracil (HY-90006) and Oxaliplatin (HY-17371) significantly inhibits tumor growth more than monotherapy and does not increase chemotherapy-related toxicity in the OCUM-2M gastric cancer xenograft model[2].
Bemarituzumab (10 mg/kg; i.p.; biweekly) significantly reduces tumor burden, recruits NK cells, and increases PD-L1-expressing cells and CD3-positive T cells in the syngeneic 4T1 mouse mammary tumor model[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CB17 SCID mice (7-8 weeks old), xenograft model of OCUM-2M human gastric cancer cells[2]
Dosage: 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg (in PBS)
Administration: Intravenous injection, twice a week
Result: Inhibited tumor growth in a dose-dependent manner.
Inhibited and regressed tumor growth starting from a dose of 1 mg/kg.
Caused complete tumor regression in 1/15 mice at the 1.5 mg/kg and 2 mg/kg doses, 4/15 mice at the 3 mg/kg dose, and 6/15 mice at the 5 mg/kg dose by day 42.
Clinical Trial
Molecular Weight

143860.00

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Bemarituzumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized FGFR-2 alpha (IIIb) Protein, Human (HEK293, His, HY-P76336) can bind Bemarituzumab. The EC50 for this effect is 5.673 ng/mL.
Purity & Documentation

Purity: 99.82%

SDS (251 KB)

COA (231 KB) SDS-PAGE (70 KB) SEC-HPLC (121 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bemarituzumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bemarituzumab1952272-74-0FGFRFibroblast growth factor receptorfirst-in-classhumanized IgG1 monoclonal antibodanticancermammary tumorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Bemarituzumab
Cat. No.:
HY-P99010
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.